Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 1-10

  Skoda Smith, Suzanne ^a   Torgerson, Troy R ^a   Ochs, Hans D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody deficiency; Common variable immune deficiency; Primary immunodeficiency disease; Subcutaneous immunoglobulin; X linked agammaglobulinemia

Indexed keywords

ANTIHISTAMINIC AGENT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; OCTAGEM; PARACETAMOL; STEROID; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ASEPTIC MENINGITIS; CHILL; CLINICAL TRIAL; DEVICE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FRACTIONATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOTENSION; IMMUNE DEFICIENCY; INJECTION SITE REACTION; KIDNEY FAILURE; MALAISE; MYALGIA; NAUSEA; OSMOLALITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIMARY IMMUNE DEFICIENCY; QUALITY OF LIFE; REVIEW; RIGOR; SUBSTITUTION THERAPY; SWELLING; THROMBOSIS; X LINKED AGAMMAGLOBULINEMIA;

EID: 77950834217     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722-728.
2. Berger M. A history of immunoglobulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368-378.
3. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease; a review of the evidence by members of the primary immunodeficiency committee of the AAAAI. J Allergy Clin Immunol. 2006;117:S525-S553.
4. Pierce CR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17:241-254.
5. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med. 1980;93: 55-56.
6. Cunningham-Rundles C, Siegel FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary immunodeficiency disease. Ann Intern Med. 1984;101:435-439.
7. Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134: 589-596.
8. Webb DB, Kendra JR, Gross E, Stamatakis JD. Infusion of intravenous immunoglobulin via implantable subcutaneous catheter. Lancet. 1991;337:1617-1618.
9. Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med. 1986;81:443-446.
10. Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162-166.
11. Hansen S, Gustafson R, Smith CIE, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol. 2002;104:237-241.
12. Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet. 1993;342:1432-1433.
13. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics. 1996;98:1127-1131.
14. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48-51.
15. Stiehm ER, Casillas AM, Finkelstein JZ, et al. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol. 1998;101:848-849.
16. Mankarous M, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, Wedgwood RJ. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med. 1988:112:634-640.
17. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies, advantages of the subcutaneous route. Biodrugs. 2007;21:105-116.
18. Smith GN, Griffiths B, Mollison D, Mollison PL. Uptake of IgG after intramuscular and subcutaneous injections. Lancet. 1972;1:1208-1212.
19. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Am. 2008;28:803-819.
20. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114-121.
21. Gardulf A. Nicolay U, Math DI, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG infusions at home. J Allergy Clin Immunol. 2004;114:936-942.
22. Grunebaum E, Levy Y, Shoenfeld Y. Novel aspects of hypogamma-globulinemic states: subcutaneous immunoglobulin treatment. Isr Med Assoc J. 2002;4:288-289.
23. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency disease. J Clin Immunol. 2006;26:265-273.
24. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94-100.
25. Gardulf A. Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol. 2006;26:177-185.
26. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1-7.
27. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365-369.
28. Quinti I, Soresina A, Agostini C, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol. 2008;9169-9199.
29. Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol. 1998;112:341-346.
30. Fasth A, Nystrom. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatrica. 2007;96:1474-1478.
31. Gardulf A, Andersson E, Lindqist M, et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. J Clin Immunol. 2001;21:150-154.
32. Arora R, Newton TC, Nelson MR. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease. Ann Allergy Asthma Immunol. 2007;99:367-370.
33. Radinsky S, Bonagura VR. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol. 2003;112:630-633.
34. Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econom. 2005;50:24-29.
35. Gardulf A, Bjorvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous immunoglobulin infusions. Clin Exp Immunol. 1993;92:200-204.
36. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65-72.
37. Gardulf A, Nicolay U. Replacement IgG therapy and self therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434-442.
38. Gardulf A, Borte M, Ochs HD, et al. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIg home therapy. Clin Immunol. 2008;126:81-88.
39. Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370-378.
40. Dams ETM, van der Meer JWM. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies. Lancet. 1995;345:864.
41. Gustafson R, Gardulf A, Hansen S, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol. 2008;152:274-279.